Business Wire
BusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex TimesBusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex TimesBusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex TimesBusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex Times
Back to front
Costco steps up push into GLP-1 weight loss prescriptions through pharmacy and healthcare services
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 4, 9:30 AM EDT

Costco steps up push into GLP-1 weight loss prescriptions through pharmacy and healthcare services

The wholesaler is moving deeper into the weight loss drug market, using GLP-1 prescriptions and related healthcare offerings as retailers compete for a share of growing demand.

Costco is pressing further into the weight loss drug market by expanding access to GLP-1 (glucagon-like peptide-1) prescriptions and offering related healthcare services, according to a report by Yahoo Finance.

GLP-1 drugs are prescription medicines designed to help with weight loss and appetite regulation. In recent years, demand has surged as more patients seek clinically supported options for obesity and related conditions, and as coverage and availability have improved unevenly across the U.S. market.

The Yahoo Finance report says Costco is accelerating its entry through a mix of GLP-1 prescriptions and supplemental healthcare services, positioning the company alongside other large retailers that have also been moving into weight management care. Walmart and Amazon, the report notes, are among the retailers pursuing similar strategies.

While Costco’s direction is clear, the report does not provide detailed information on the specific program structure, participating providers, pricing, fulfillment model, or the exact scope of locations or service areas covered. It also does not disclose whether Costco is relying on in-store pharmacy operations, partnerships with healthcare intermediaries, or a centralized telehealth workflow.

For shoppers and investors, the strategic thrust is nonetheless recognizable. Retailers bring advantages to medicine fulfillment and patient acquisition, including large customer bases, established pharmacy footprint considerations, and strong consumer traffic. In weight loss care, that combination matters because supply, prescribing capacity, and ongoing program adherence can be bottlenecks, and because patient retention hinges on follow-up and coordinated support.

The broader retail and consumer sector context is that GLP-1 services are becoming a competitive battleground where companies try to capture both near-term prescription volumes and longer-term engagement. Unlike purely consumer packaged goods, weight management care is sticky, requiring continuity, monitoring, and services that can extend beyond a single medication fill.

As with many early moves in the retail healthcare model, what is not yet fully spelled out in the report is the commercial payoff timing and how Costco will manage clinical and operational risks. Costco’s rollout pace, partner involvement, and any constraints tied to drug supply or prescribing standards are not detailed in the Yahoo Finance post.

In the near term, investors and customers will likely watch for additional disclosures on the program’s scale, how eligibility and prescriptions are handled, and whether Costco expands access beyond initial pilots. The pace of adoption and any changes in pharmacy and healthcare service metrics, if later reported, will be key indicators of how meaningful GLP-1 services become to Costco’s broader operating picture.

Why It Matters

  • If executed well, retail-based GLP-1 services could create a new, higher-frequency healthcare revenue stream compared with typical retail category cycles.
  • Execution quality matters because weight loss care depends on prescribing capacity, ongoing support, and supply availability, not just marketing.
  • Competition among large retailers may accelerate patient acquisition and raise expectations for convenience and follow-up support.
  • Costco’s approach could influence how other consumer companies structure partnerships and service delivery in prescription healthcare.
  • The lack of disclosed rollout and economics means investors will need further updates to gauge financial impact.

Sources

Key Facts

  • Costco is expanding its participation in weight loss drug access by pushing further into GLP-1 prescriptions and related healthcare services.
  • GLP-1 drugs are prescription medicines aimed at weight loss and appetite regulation.
  • A Yahoo Finance report frames Costco’s move as part of a wider retailer push into weight management care.
  • The report indicates Costco is moving alongside other major retailers pursuing similar GLP-1 strategies, including Walmart and Amazon.
  • The available report does not detail program mechanics such as partner structure, location coverage, or pricing.

Retail & Consumer Related

Aug 31, 11:38 PM EDT
The Apex Times

DICK’S Sporting Goods’ guidance cut rattles NIKE, highlighting how weakness at a key specialty retailer can spread

After DICK’S Sporting Goods missed expectations and lowered its outlook, the market treated it as a stress test for brands tied to the retailer’s demand. Investors focused on NIKE, Inc. as DICK’S depends heavily on the Swoosh brand, turning one company’s slowdown into a wider caution announcement for the consumer supply chain.

DICK’S Sporting Goods’ guidance cut rattles NIKE, highlighting how weakness at a key specialty retailer can spread
The Apex Times
Aug 31, 2:06 PM EDT
The Apex Times

Walmart climbs as oil at $90 bolsters the “defensive” appeal of retailers

Investors are treating cheaper-to-own retail as a buffer again, after a sharp move in crude oil toward $90. The shift could help Walmart capture shoppers “trading down,” but higher fuel and inventory costs also pose a risk to the cash profits that support its valuation.

Walmart climbs as oil at $90 bolsters the “defensive” appeal of retailers
The Apex Times
Costco steps up push into GLP-1 weight loss prescriptions through pharmacy and healthcare services | The Apex Times